We are live on
!
Find out more
Loomis, Sayles & Company Portfolio holdings
AUM
$74.3B
1-Year Est. Return
24.01%
This Fund
S&P 500
This Quarter
Est. Return
+5.89%
1 Year Est. Return
+24.01%
3 Year Est. Return
+109.67%
5 Year Est. Return
+145.58%
10 Year Est. Return
+623.08%
AUM
$53.6B
AUM Growth
+$2.66B
(+5.2%)
Cap. Flow
+$86.8M
Cap. Flow
% of AUM
0.16%
Top 10 Holdings %
Top 10 Hldgs %
37.17%
Holding
821
New
56
Increased
227
Reduced
258
Closed
253
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$86.2M |
| 2 |
Alcon
ALC
|
+$81.8M |
| 3 |
NVIDIA
NVDA
|
+$76M |
| 4 |
Corning
GLW
|
+$50.4M |
| 5 |
UnitedHealth
UNH
|
+$42.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Novartis
NVS
|
+$67.4M |
| 2 |
Factset
FDS
|
+$62M |
| 3 |
Euronet Worldwide
EEFT
|
+$42.3M |
| 4 |
Bank of America Series L
BAC.PRL
|
+$39.5M |
| 5 |
OPLN
Openlane
OPLN
|
+$31.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.75% |
| 2 | Consumer Discretionary | 17.74% |
| 3 | Financials | 11.65% |
| 4 | Healthcare | 11.2% |
| 5 | Communication Services | 10.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Colgate-Palmolive
CL
$74.4B
| $769M | 1.44% |
10,724,524
+26,496
| +0.2% | +$1.88M |
|
|
VAR
27
DELISTED
Varian Medical Systems, Inc.
VAR
| $733M | 1.37% |
5,386,064
-11,495
| -0.2% | -$1.54M |
|
28
Yum China
YUMC
$16.3B
| $681M | 1.27% |
14,749,829
+157,181
| +1% | +$6.82M |
|
|
29
Bristol-Myers Squibb
BMY
$130B
| $649M | 1.21% |
14,320,964
+1,850,195
| +15% | +$86.2M |
|
|
30
Novartis
NVS
$294B
| $642M | 1.2% |
7,028,136
-796,514
| -10% | -$67.4M |
|
31
SLB Ltd
SLB
$74.1B
| $623M | 1.16% |
15,685,836
+106,640
| +0.7% | +$4.3M |
|
32
Amgen
AMGN
$220B
| $614M | 1.15% |
3,331,864
+1,113
| +0% | +$199K |
|
33
American Express
AXP
$236B
| $510M | 0.95% |
4,135,253
+3,272
| +0.1% | +$384K |
|
34
Merck
MRK
$317B
| $473M | 0.88% |
5,906,982
+2,114
| +0% | +$162K |
|
35
Automatic Data Processing
ADP
$107B
| $416M | 0.78% |
2,516,941
-12,045
| -0.5% | -$1.96M |
|
36
Ford
F
$56.3B
| $272M | 0.51% |
26,629,004
-70,926
| -0.3% | -$699K |
|
|
37
Corning
GLW
$135B
| $261M | 0.49% |
7,863,564
+1,571,327
| +25% | +$50.4M |
|
38
Roper Technologies
ROP
$39B
| $199M | 0.37% |
542,145
+15,680
| +3% | +$5.57M |
|
39
Danaher
DHR
$140B
| $197M | 0.37% |
1,553,352
+143,296
| +10% | +$17M |
|
40
Under Armour
UAA
$2.88B
| $169M | 0.31% |
6,647,558
+349,972
| +6% | +$8.2M |
|
41
Marriott International
MAR
$94.2B
| $162M | 0.3% |
1,151,853
+74,644
| +7% | +$9.9M |
|
|
42
UnitedHealth
UNH
$375B
| $161M | 0.3% |
661,206
+175,788
| +36% | +$42.3M |
|
43
Sherwin-Williams
SHW
$89.7B
| $151M | 0.28% |
991,650
+63,963
| +7% | +$9.56M |
|
44
MSCI
MSCI
$41.6B
| $126M | 0.23% |
525,915
-6,813
| -1% | -$1.53M |
|
45
Northrop Grumman
NOC
$79.2B
| $125M | 0.23% |
385,574
+60,370
| +19% | +$18M |
|
46
Accenture
ACN
$104B
| $119M | 0.22% |
646,700
+34,184
| +6% | +$6.14M |
|
47
Mettler-Toledo International
MTD
$28.5B
| $111M | 0.21% |
132,688
+7,249
| +6% | +$5.47M |
|
48
M&T Bank
MTB
$36.5B
| $111M | 0.21% |
653,456
+42,225
| +7% | +$7M |
|
49
Texas Instruments
TXN
$254B
| $110M | 0.2% |
954,378
+57,352
| +6% | +$6.41M |
|
50
CBRE Group
CBRE
$43.8B
| $104M | 0.19% |
2,025,893
+132,148
| +7% | +$6.57M |
|
Similar funds
CBU
BC
Loomis, Sayles & Company's Q2 2019 Portfolio in Review
As of Q2 2019, Loomis, Sayles & Company held 821 positions worth $53.6B, up 5.2% from $50.9B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
Loomis, Sayles & Company's Q2 2019 filing shows 56 new, 227 increased, 258 reduced and 253 closed positions. Its largest new stake was Alcon: 1,393,674 shares worth $86.5M. The largest sale was Novartis, an estimated $67.4M.
By sector, the portfolio is most concentrated in Technology at 21% of assets, up from 20% a quarter earlier, followed by Consumer Discretionary and Financials.
- Loomis, Sayles & Company's largest Q2 2019 buy was Alcon: 1,393,674 shares worth $86.5M.
- Loomis, Sayles & Company added most to Bristol-Myers Squibb in Q2 2019, an estimated $86.2M increase.
- Loomis, Sayles & Company's biggest Q2 2019 reduction was Novartis, cutting an estimated $67.4M.
- Loomis, Sayles & Company fully exited RingCentral in Q2 2019, selling an estimated $30.4M.
- Loomis, Sayles & Company's ten largest holdings make up 37% of its $53.6B portfolio in Q2 2019.
- Loomis, Sayles & Company opened 56 new positions and closed 253 in Q2 2019.
- Loomis, Sayles & Company's portfolio value rose 5.2% quarter-over-quarter to $53.6B.
Based on Loomis, Sayles & Company's 13F filing for Q2 2019, filed 14 Aug 2019.